ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
18 déc. 2024 08h00 HE
|
ViGeneron GmbH
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated...
MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
06 oct. 2024 11h13 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
04 oct. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
03 oct. 2024 16h41 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
30 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
30 sept. 2024 14h35 HE
|
Bernstein Liebhard LLP
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
25 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
23 sept. 2024 01h45 HE
|
Bernstein Liebhard LLP
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
21 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
17 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...